Cancer Biomarker Market Report By Product (Proteins, Antibodies, Gene cDNA Clones, ELISA Kits), By Cancer Type(Lungs, Breast, Leukemia, Melanoma), By Application(Diagnostic, Prognostic, Predictive)

Cancer Biomarker Market in the Global Industry Landscape

Cancer biomarker indications are used for early detection of cancer and to mark the route of development of cancer cells. Early detection can help to save millions of lives every year and thus reduce the cancer mortality rate. New estimated cancer cases in 2018 in US is 1,735,350, of which 609,640 are the number of estimated deaths in the same year. As reviewed the various representative examples that uses multiple approaches for each biomarker, and all these cases have demonstrated that as compared to traditional techniques, the multidisciplinary technology-based cancer diagnostics are swaying the cancer risk assessment, diagnosis and prognosis. On the other hand, single biomarker today is incapable to indicate the cancer risk for all the body organs. They work precisely to specific areas. Moreover, breast cancer is one of the common type of cancers and the biomarkers used for detection are not yet validated by the researchers. Therefore there is no FDA approved biomarkers for cancer. In 2017, approximately 41.070 U.S. women are anticipated to die from breast cancer. Whereas in 2011, 508.000 women died of breast cancer all over the world. In developed countries, breast cancer survival rates ranges from over 80% to below 40% in low-income countries.

Our Global Cancer Biomarker Market can be segmented on the following basis:

By Product Type

• Cancer Biomarker Proteins
• Cancer Biomarker Antibodies
• Cancer Biomarker Gene cDNA Clones
• Cancer Biomarker ELISA Kits

By Cancer Type

• Lungs Cancer
• Breast Cancer
• Leukemia
• Melanoma
• Others

By Application

• Diagnostic Biomarkers
• Prognostic Biomarkers
• Predictive Biomarkers

By Geography

• North America Cancer Biomarker Market (US, Canada) {Market Share (%), Market Size (USD Billion)}
• Europe Cancer Biomarker Market (UK, France, Italy, Germany, Spain, Sweden, Russia, Netherlands, Norway and Rest of Europe) {Market Share (%), Market Size (USD Billion)}
• Middle East and Africa Cancer Biomarker Market (GCC Countries, North Africa, South Africa and Rest of Middle East & Africa) {Market Share (%), Market Size (USD Billion
• Latin America Cancer Biomarker Market (Brazil, Mexico and Rest of Latin America) {Market Share (%), Market Size (USD Billion)}
• Asia Pacific Cancer Biomarker Market (China, Japan, India, Singapore, South Korea, Australia and Rest of Asia-Pacific) {Market Share (%), Market Size (USD Billion)}

Global Cancer Biomaker Market Outlook comprises of the following data:

• Coverage Numbers and Type of Cancer Biomarkers in Clinical Use, 2012-2017
• Coverage Numbers and Type of Cancer Biomarkers Undertrials, 2015-2018
• Number of People Newly Diagnosed of Cancer, 2015 and 2016-2024
• Number of People Died of Cancer, 2015 and 2016-2024

In 2016 on the basis of product type, protein biomarkers segment accounted for largest market share due to high potential in multiple applications such as diagnostics, prognostics R&D. Moreover protein biomarker are of low cost as compared to other types of cancer biomarkers.

In terms of gene-expression studies, genomic microarrays represent a highly powerful technology. Over the past decade, increasing application of gene-expression profiling across the sites has been witnessed. Thus this growth has resulted in the cancer sub-classification theory, large number of diagnostic discoveries of cancer biomarkers and insights further into cancer pathogenesis.

In 2017, Human Longevity, Inc. (HLI), health intelligence company powered by genomics, had announced an agreement with Merck KGaA, Darmstadt, Germany, an agreement between the two companies towards use of machine learning in pioneering the application of advanced genomics and expert analysis in order to transform medical use and drug development of next generation therapeutics.

Expert Analysis: Currently there is lack of regulatory guidelines related to the cancer biomarkers. A biomarker is qualified based on the strength of evidence during the evaluation of the biomarker. However, continuous coordination is witnessed among the industry, NIH, regulatory agencies, and academia towards the discovery of novel biomarkers, its qualification and validation.